Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections

Revised Ms SBMB 2020_166

Jose Manuel Quesada-Gomez\textsuperscript{a,b}, Marta Entrenas-Castillo\textsuperscript{c}, Roger Bouillon\textsuperscript{d,*}

\textsuperscript{a} Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). Hospital Universitario Reina Sofía, Universidad de Córdoba, Fundación Progreso y Salud, Avda. Menéndez Pidal s/n, 14004, Córdoba, Spain

\textsuperscript{b} CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Spain

\textsuperscript{c} UGC de Neumología. Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). Hospital Universitario Reina Sofía, Universidad de Córdoba, Avda Menéndez Pidal s/n, 14004, Córdoba, Spain

\textsuperscript{d} Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental Endocrinology, KU Leuven, Herestraat, ON 1/902, 3000, Leuven, Belgium

ARTICLE INFO

Keywords:
Vitamin D, vitamin D3 or cholecalciferol
Calcifediol or 25-hydroxyvitamin D3
1α,25(OH)\textsubscript{2}D or 1α,25-dihydroxyvitamin D or calcitriol
Coronavirus
SARS-CoV-2
Acute respiratory distress syndrome (ARDS)
Cytokine storm
Lung diseases
Renin-angiotensin system
Hypercoagulability

ABSTRACT

Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor. Several randomized clinical trials using either oral vitamin D or oral Calcifediol (25OHD) are ongoing. Based on a pilot study, oral calcifediol may be the most promising approach. These studies are expected to provide guidelines within a few months.

1. Introduction

The coronavirus disease 2019 (COVID-19) is rapidly causing worldwide morbidity and mortality. While most infected people will recover after a mild to modest course of the disease, some patients, especially older people or those with other major diseases, will suffer serious morbidity and a high mortality risk. In the absence of vaccines, some therapeutic interventions have some proven benefits (such as convalescent plasma \cite{1} and remdesivir \cite{2}, whereas other approaches (including vitamin D) that may influence the course of the disease deserve special attention.

The vitamin D endocrine system is well known for its beneficial effects on calcium and bone homeostasis, especially in children and elderly subjects. Moreover, it may have several extra-skeletal effects \cite{3} especially on the immune system and lung function. All cells of the immune cells can express the vitamin D receptor (VDR) and most cytokines, produced by or regulating these immune cells are under the coherent control of the active vitamin D hormone, 125(OH)\textsubscript{2}D. Indeed, in essence, 1α,25(OH)\textsubscript{2}D activates the native immune defense system while tapering down the acquired immune system \cite{3–5}. In addition, antigen-presenting cells and mononuclear cells can express CYP27B1, the essential enzyme for the local, auto/paracrine production of 1α,25(OH)\textsubscript{2}D in the immune system. Vitamin D deficiency may predispose to increased risk of infections, and vitamin D supplementation may decrease the risk of upper respiratory infections \cite{6}. The lung epithelium also expresses the VDR and CYP27B1 and may be an important target tissue for the vitamin D endocrine system \cite{7}. Therefore, there may be many potential links between viral infections such as COVID19 and vitamin D status.

In this Viewpoint, we summarize how activation of the vitamin D Receptor (VDR) may be able to decrease acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). We therefore will first review the major mechanisms underlying ALI and ARDS in patients with viral (including Coronavirus) infections. Thereafter, we present an

https://doi.org/10.1016/j.jsbmb.2020.105719

Received 4 May 2020; Received in revised form 25 May 2020; Accepted 7 June 2020
Available online 11 June 2020

0960-0760/ © 2020 Elsevier Ltd. All rights reserved.
overview of the ongoing RCTs that hopefully will allow to better describe the implications of vitamin D deficiency or its rapid correction for the course of this disease.

2. Major mechanism involved in the pathogenesis of ARDS

The occurrence and severity of Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus Disease 2019 (COVID–19) is a life-threatening condition and a major determining factor of the prognosis [8]. Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–associated pulmonary edema or ARDS have pulmonary inflammation, thick mucus secretions in the airways, elevated levels of proinflammatory cytokines, extensive lung damage, and microthrombosis [9]. Almost 20 % of the hospitalized patients (including ICU and non-ICU patients) with COVID-19 developed ARDS and, despite recent improvements in mechanical ventilation strategies and supportive care, about 65 % of patients with ARDS died [10]. In ARDS, the epidemiological and morbidity/mortality patterns are similar regardless of the trigger [11]. ARDS is a pivotal component of the pathophysiological processes by which patients with severe COVID-19 proceed to develop multiple organ dysfunction with high mortality [8]. ARDS onset is often rapid and progressive, it appears approximately nine days after the onset of severe COVID-19 infection [12], and patients with ARDS died a mean of 20 days after the onset of the symptoms or about 9–11 days after ICU admission [13]. The disease is difficult to manage at a late stage of the disease and early treatment is thus critical to control the progression of infection and improving the prognosis of patients with ARDS. There is currently no Food and Drug Administration-approved effective pharmacologic treatment for ARDS, and management remains supportive with lung-protective mechanical ventilation [14,15]. ARDS is the common immune-pathological event for SARS-CoV-2, SARS-CoV, and MERS-CoV infections [8]. The main pathophysiological mechanisms involved in ARDS are:

1) A cytokine storm or the uncontrolled, sometimes fatal, inflammatory response resulting from the release of large amounts of pro-inflammatory cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α, TGFβ, etc.) and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10, etc.) by immune effector cells during SARS-CoV infection [16,17]. Similar to those infected with SARS-CoV, patients with severe SARS-CoV infection showed elevated levels of serum IL-6, IFN-α, and CCL5, CXCL8, CXCL10 compared to those with mild-moderate disease [18]. In addition, the excessive activation and recruitment of neutrophils into inflamed interstitium and alveolar space with disruption of the endothelial-epithelial barrier and alveolar damage exacerbates the pathogenesis of ARDS and may indicate a poor clinical outcome [19]. The chemokine (C-X-C motif) ligand 8 (CXCL8) and interleukin-8, the chemokine that modulates innate and adaptive immune responses by recruiting inflammatory cells (i.e., neutrophils, T lymphocytes and NK cells) to the sites of inflammation, are considered to be the archetypal neutrophil chemoattractants [20]. By binding to its receptor CXCR3, CXCL10 can induce chemotaxis, apoptosis, cell growth and angiogenesis [21]. The limited data so far in patients infected with SARS-CoV-2 confirmed the presence of high amounts of pro-inflammatory cytokines and chemokines. Moreover, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, and TNFα than those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity [9].

2) The activation of the ren angiotensin system (RAS) with decrease of angiotensin converting enzyme ACE2 have been implicated in the pathogenesis of acute respiratory distress syndrome [22]. Indeed, local or systemic inflammatory reactions may activate the RAS whereby angiotensin II generated by ACE is able to induce lung damage, whereas ACE2 transforms angiotensin II into smaller peptides with lung protective effects. The alteration of the balance between the levels of the enzymes ACE and ACE2 that affects the endogenous ratio of Ang II:Ang(1–7), with elevation of angiotensin II, is key to the development of ALI and ARDS in both animal models [22,23] and humans [24,25]. It is important to highlight that SARS-CoV-2 does not use other coronavirus receptors such as aminopeptidase N and dipeptidyl peptidase 4 [26], but SARS-CoV-2 uses ACE2 as a cellular entry receptor [27]. 83 % of cells expressing ACE2 are type II alveolar epithelial cells (AE2II), suggesting that these cells may serve as a reservoir for viral invasion [28]. Interestingly, Kuba et al [26] found that the expression of ACE2 (but not the ACE) in lung tissues was significantly downregulated in mice, decreasing the availability of ACE2 during SARS-CoV-2-induced lung injury. ACE2 counter-regulates the effects produced by Ang II by converting Ang II to Ang(1–7), activates Mas to repress the signaling pathways of STAT3 and extracellular signal-regulated kinases (ERK) [29], and acts as an anti-inflammatory factor [30]. In this way, a lung protective mechanism is lost and SARS-CoV infection becomes more lethal, with exaggerated neutrophil accumulation, increased pulmonary vascular permeability and exacerbated pulmonary edema, which eventually lead to ARDS. Both mechanisms lead to an extensive inflammatory process, with activation, recruitment and influx of activated neutrophils and macrophages in the alveolar space due to the disruption of the alveolar epithelial barrier with diffuse alveolar damage. The alveolus is filled with activated neutrophils, cytokines/chemokines and protein-rich exudate. In this state, the lungs cannot provide enough oxygen to the blood for the body’s vital organs [8]. Moreover, the state of hyperinflammation and activation of the RAS are intimately involved in altering the coagulation cascade [31], which in cooperation with endothelial cell infection and endotheliitis [32] leads to a more prothrombotic status seen in ARDS during SARS-CoV-2 infections. The dysregulation of the coagulation cascade and the subsequent formation of intra-alveolar or systemic fibrin clots and thrombotic complications are prominent findings in coronavirus infections associated with ARDS [33,34]. Another consequence is the potential risk of fibrosis [35] with impaired lung function after recovery in the course of natural history of the disease [36].

3. Potential role of activation of the VDR in ARDS

Vitamin D deficiency is associated with an increased risk of upper respiratory infection. A recent meta-analysis using about 10,000 individual participants data from 25 RCTs, concluded that vitamin D supplementation reduced the risk of upper respiratory infections by about 19 % [6]. Patients with severe vitamin D deficiency experienced the greatest benefit. Whether this conclusion would also apply to corona virus infections is unknown and will not be discussed here as we want to focus on the potential role of vitamin D on ARDS.

Several studies have suggested that the vitamin D/VDR signaling pathway may provide some beneficial effects in LPS-induced ARDS mediated by several mechanism (Fig. 1 and 2) such as (1) decreasing the storm of cytokines and chemokines; (2) regulating the renin-angiotensin system; (3) modulating neutrophil activity; (4) maintaining the integrity of the pulmonary epithelial barrier and (5) stimulating epithelial repair [37–40].

(1) VDR is highly expressed in the cuboidal alveolar type II cells (ACII) of the lung [7] [37]. Overexpression of VDR exerts anti-inflammatory effects in the lung [41]. VDR-knockout mice experienced more severe acute lung injury (ALI) than wild-type mice, following LPS treatment. The endocrine system of vitamin D has been shown, in various in vitro models, to inhibit the production and release of cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α) and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10) involving ARDS [7,42–46]. The calcitriol/VDR signaling may also protect against ALI by inhibiting the angiotopoietin-2-TEK receptor tyrosine kinase-myosin light-chain kinase pathway [39]. Thus, 1α,25(OH)2D is important in
maintaining the structure and function of epithelial barriers in multiple tissues mediated by alveolar epithelial tight junctions and gene regulation of occludin and zonula occludens-1 (ZO-1) expression. 1α,25(OH)2D also inhibits neutrophil recruitment in an animal model of acute lung injury, due to its inhibitory effect on cytokines. There is ample evidence that 1α,25(OH)2D/VDR is a powerful negative regulator of renin-angiotensin system (RAS). Indeed, renin is increased in VDR null mice. Similarly, 1α-hydroxylase-deficient mice exhibit increased activity of the intrarenal RAS that is downregulated with the administration of 1α,25(OH)2D. Chronic vitamin D deficiency may induce RAS activation. 1α,25(OH)2D inhibits renin, ACE and Ang II expression, and induces ACE2 levels in LPS-induced ALI. In addition, dysregulation of local and circulating RAS, with enhanced ACE/Ang II expression levels and reduced ACE2/Ang-(1–7) expression levels, was reported to contribute to ischemia-reperfusion-induced ALI in mice. Therefore, vitamin D may attenuate LPS-Induced ALI by, at least partially, inducing ACE2 being potentially harmful or beneficial for virus induced lung (or other tissue) damage has generated intensive debate also related to the use of angiotensin antagonists in hypertensive patients. Overall, most experts concluded that the potential beneficial effects of ACE2 on heart and lungs may overrule its role in virus entrance.

4. Neutrophils, pneumonitis and vitamin D

Increased neutrophil infiltration is part of this picture of viral pneumonitis and ARDS and aims to destroy the infiltrating microorganisms by oxidative burst and phagocytosis. Neutrophils can also kill pathogens by the formation of Neutrophil Extracellular Traps (NETs). Prior reports have linked aberrant NET formation to pulmonary diseases, thrombosis, mucous secretions in the airways and cytokine production. At autopsy of a patient who died from corona virus pneumonia, intensive neutrophil infiltration and excess NETs were observed. Whether this is part of a defense strategy or whether suppression of such NET formation would be beneficial is unknown. The role of VDR activation in neutrophils has not been extensively studied. One study however reported that 125(OH)2D (in vitro) increased NET formation in neutrophils from
5. Maintaining the integrity of the pulmonary epithelial barrier and stimulating epithelial repair [37–40]

The epithelial, cuboidal alveolar coating type II cells (ACII), which facilitate the entry of virus into the body, have high levels of multiple viral process-related genes, including regulatory genes for viral processes, viral life cycle, viral assembly, and viral genome replication [28]. Therefore, these cells are the major target cells for viral attack. As a result of the high basal expression of 1α-hydroxylase activation and low expression of the inactivating enzyme (24-hydroxylase), the ACII are able to convert circulating 25OHD into 1α,25(OH)2D [7], just as several cells of the immune system (antigen presenting cells and monocytic cells). 1α,25(OH)2D generated by ACII can act in an autocrine or paracrine fashion and, like cells of the immune system, increase the expression of vitamin D regulated genes with important innate immune functions (antimicrobial cathelicidin peptide gene and the TLR co-receptor CD14). In addition, in a viral infection model, dsRNA increased the expression of the 1α-hydroxylase and synergizes with calcifediol and calcitriol sequentially to induce cathelicidin [64]. Apart from defensins (such as cathelicidin), 1α,25(OH)2D also stimulates several genes in these ACII cells with favorable effects such as stimulation of surfactant factor and tight junction genes [65]. In a mouse model, 1α,25(OH)2D attenuated LPS-induced lung injury by promoting epithelial cell proliferation, and inhibited apoptosis and epithelial mesenchymal transition, suggesting that VDR activation may have therapeutic potential for the resolution of ARDS [40]. Similar beneficial effects were observed in other lung injury models [37,66].

6. Coagulation and thrombosis

Inflammation is an extremely complex pathophysiological process that is closely related to hemostasis. The activation of both systems is interdependent in a cycle of positive feedback, with one process promoting the effects of the other process and vice versa. Inflammation promotes a prothrombotic state. This crosstalk is mediated by procoagulant factors, pro-inflammatory cytokines, chemokines, adhesion molecules, tissue factor (TF) expression, platelets and endothelial cells [67]. The anti-thrombotic effects of vitamin D is well documented in preclinical studies. VDR knockout mice display increased platelet aggregation. Their gene expression of antithrombin (liver) and thrombomodulin (aorta, liver and kidney) were downregulated, whereas tissue factor expression in liver and kidney were upregulated. VDR stimulation with 1α,25(OH)2D and/or its agonist maxacalcitol downregulated TF and upregulated thrombomodulin gene expression in monocytic cells, previously stimulated by tumor necrosis factor (TNF), lipopolysaccharides (LPS), and oxidized LDL (ox-LDL) [68]. VDRKO mice manifested exacerbated multi-organ thrombus formation after exogenous lipopolysaccharide injection with an increase in endothelial adhesion molecules, a decrease in NO production, and increased platelet aggregation [69]. 1α,25(OH)2D and its analogue paricalcitol significantly blunted the expression of TF, and its procoagulant activity, induced by the proinflammatory cytokine TNF-α in human aortic vascular smooth muscle cell (VSMCs), in a NF-κB-dependent manner. This was accompanied by the up-regulation of TF signaling mediator...
protease-activated receptor 2 (PAR-2) [70]. Observational data in humans revealed an association between low levels of 25OHD and the development of deep venous thromboembolic (DVT) [71] events in patients with ischemic stroke. Conversely, a significant positive association was found between serum levels 25OHD (> 20 ng/mL) and TF pathway inhibitor (TFPI) (a dual inhibitor of coagulation by binding to both TF/Factor VIIa complex as well as Factor Xa) [72]. Most intervention studies however did not show clear benefits of vitamin D supplementation on major cardiovascular events, although most study subjects were not severely vitamin D deficient at baseline [3].

7. Clinical consequences: Vitamin D status and ADRS during corona virus infection

Despite the potential effects of VDR activation on ARDS or lung injury as described above, serious caution is needed before concluding that vitamin D supplementation may improve the outcome of SARS-CoV-2 infections. Indeed, as VDR/1α,25(OH)2D activation regulates a very large number of genes, mostly in cluster patterns, there has been a lot of speculations on the beneficial effects of vitamin D supplementation for a wide variety of (major) diseases, such as cancer, infections or diabetes [3,73]. However, several recent meta-analyses of vitamin D supplementation did not confirm such extra-skeletal health effects. The study participants, however, were mostly vitamin D replete adults and therefore it may well be that only (severely) vitamin D deficient subjects may benefit from vitamin D supplementation. There was one remarkable observation relevant to lung diseases. In a sub study of the New Zealand VIDA trial [74], vitamin D supplementation improved the lung function (expiratory volume in 1 s) in patients with asthma, COPD or in ever-smokers, especially when vitamin D deficient at baseline.

Vitamin D deficiency is highly prevalent around the world as about 7% of the world population has severe deficiency and about 40% live with modest deficiency [75]. In addition, patients with severe acute disease or respiratory distress syndrome (ARDS) [76–78] are even more deficient than control subjects. Studies are currently being carried out specifically on COVID-19 and vitamin D status [79,80]. Correction of vitamin D deficiency is relatively easy by either increased exposure to sunlight (unlikely for patients with ARDS), oral or parenteral vitamin D supplementation, or supplementation with 25OHD (calcifediol). To correct vitamin D deficiency in severely sick patients much higher doses than usual are needed [81], probably related to impaired hepatic conversion of vitamin D into 25OHD [82]. Calcifediol may have some advantages over the native vitamin D: it has a more reliable intestinal absorption (close to 100%) and can rapidly restore serum concentrations of 25OHD as it does not require hepatic 25-hydroxylation. This is especially relevant in clinical situations whereby rapid restoration of serum 25OHD is desirable and CYP2R1 expression is compromised. Such impaired CYP2R1 activity has been well demonstrated in several animal models of obesity, diabetes or glucocorticoid excess [82]. This has also been demonstrated in patients with COPD or asthma [83]. In addition, calcifediol is about 3-fold more potent when compared to oral vitamin D3 in postmenopausal women [84]. An additional advantage of oral calcifediol is a more linear response curve, whereas there is a plateau effect with increasing doses of oral vitamin D3 [84]. The tissue effects of restoring vitamin D status may be due to circulating serum 125(OH)2D or, more likely, on the local conversion of 25OHD into the active hormone in pulmonary alveolar cells, immune cells or other potential target tissues.

8. Ongoing randomized controlled trials (RCTs)

It seems logical to correct vitamin D deficiency in all subjects for reasons unrelated to viral infection [8]. The available evidence suggests that the stimulation of VDR in patients with Coronavirus SARS-CoV-2 infection, may reduce Acute Respiratory Distress Syndrome (ARDS), with possibly beneficial effects on admission to intensive care unit (ICU) and deaths in the course of the disease. SARS-CoV-2 infection has been a challenge for clinicians involved in the diagnostic and therapeutic management of infected patients. The absence of specific treatment generated many trials but so far without final conclusions, except for some beneficial effect from treatment with convalescent plasma [1] or remdesivir [2,85]. The same holds true for testing the potential benefits of vitamin D or calcifediol supplementation of patients with SARS-CoV-2 infections. According to the NIH Trialnet database several observational and intervention studies are running:

1) Vitamin D on Prevention and Treatment of COVID-19 (NCT04334005) is a randomized, double-blind trial with a start date of April 10th 2020 and an end date of June 30th, 2020. The number of participants is 200 and the study population are patients infected with COVID-19. The intervention group will receive a single dose of 25,000 IU of vitamin D and the primary outcome measures are a composite of cumulative death (i.e. mortality) for all causes and for specific causes.

2) Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations (LEAD COVID-19) (NCT04363840) is a randomized parallel assignment (Open Label) study with a start date of May 2020 and an end date of December 2020. The number of participants is 1080 and the study population are patients infected with COVID-19. The intervention group will receive either aspirin 81 mg once daily versus aspirin 81 mg once daily for 14 days plus a dietary supplement of 50,000 IU of vitamin D, to be taken orally once weekly for 2 weeks. The primary outcome is hospitalization for COVID-19 symptoms.

3) An Open Label Phase II Pilot Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection (HELPCOVID-19) (NCT04335084) is an open label trial, with assignment of participants to a single group, with start date April 2020 and end date July 2020. The number of participants is 600. The intervention is the use of hydroxychloroquine and a dietary supplement of vitamin C, vitamin D and zinc. The main outcome is the prevention of COVID-19 symptoms as recorded in a daily diary.

4) Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected with COVID-19 (ZnD3-CoVici) (NCT04351490) is a randomized open label parallel assignment trial with a start date April 2020 and end date July 2020. The number of participants is 3140 and the intervention is zinc gluconate capsule (15 mg x 2 per day) “25 – OH-cholecalciferol drinkable solution 10 drops (2000 IU)” (precise dosing in microgram not mentioned) per day for 2 months. The main outcome is the survival rate in asymptomatic subjects at inclusion.

5) COVID-19 and Vitamin D Supplementation is a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial) (NCT04344041). It is an open label trial with random assignment and start date April 2020 and end date July 2020. The number of participants is 260 subjects with coronavirus infection. The intervention is either a single dose of cholecalciferol 400,000 IU compared to a single dose of 50,000 IU. The main outcome is number of deaths from any cause during the 14 days following inclusion and intervention.

6) WEST 2020D. Impact of vitamin D deficiency on prognosis of patients with novel coronavirus pneumonia (COVID-19). No additional information on this study is available but it looks to be an observational study.

7) Chinese Clinical Trial Registry. The relationship between Vitamin D and novel coronavirus pneumonia (COVID-19). More detailed information is missing but it seems to be an observational study.

8) In Spain, based on a pilot study carried out at the Reina Sofia University Hospital (Córdoba) in 76 hospitalized patients demonstrating a reduced ICU admission by more than 50% among patients assigned to calcifediol treatment, a trial of calcifediol supplementation started on April 29th 2020. The trial is registered as "Prevention and treatment with Calcifediol of Coronavirus induced acute respiratory syndrome (SARS) COVID-19 (COVIDIOL)" (NCT04366908). It is a multi-center, randomized, open-label clinical trial to study the efficacy
and safety of calcifediol in hospitalized patients with confirmed SARS-CoV-2 infection causing respiratory disease undergoing treatment with the best available therapy administering Calcifediol or not (calcifediol in soft capsules: 0.532 mg on the day of admission and 0.266 mg on day 3 and 7 and then weekly until discharge or ICU admission). Admission to Intensive Care Unit or death are the primary outcomes.

9. The Tehran University of Medical Sciences (Iran), in collaboration with the Boston University, is responsible for an Interventional Clinical Trial registered as “Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults (Oral 25-hydroxyvitamin D3 and COVID-19)”. It is a multicenter randomized double-blinded placebo-controlled clinical trial with parallel groups and allocation 1:1. (NCT04386850). All subjects in a stratified random sampling method based on age, sex, BMI and serum level of 25(OH)D (< 10 ng/dl vs 10 to 20 ng/dl) with serum calcium < = 10.6 mg/dl will be recruited in the 25OHD3 or placebo group. Subjects in the case group will receive 25 mcg of 25OHD3 once daily at bedtime for 2 months and the control group will receive placebo daily for 2 months. Part of the study will deal with patients testing positive for COVID-19 and another arm of the study will evaluate the preventive potential of calcifediol by using the same treatment protocol for the health care providers and hospital workers with a negative test for COVID-19, or a close patient relative with a negative test for COVID-19 who lives with the infected patients. The Study Start Date was April 14th, 2020 with Estimated Primary Completion Date on November 15th, 2020, planning to enroll 1500 subjects.

In conclusion, coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of SARS-CoV-2 pneumonia is ARDS mediated by a variety of mechanisms that may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor. Several randomized clinical trials using either oral vitamin D or oral calcifediol (25OHD3) are ongoing and should provide guidelines within a few months.

Author statement

All authors declare that they have not submitted the present MS elsewhere and declare no COI for this MS Roger Bouillon has received lecture fees from Abiogen, Procter and Gamble, Fresenius, FAES elsewhere and declare no COI for this MS. Roger Bouillon has received extraskeletal action of vitamind:current evidence and outstanding questions, J.M. Quesada-Gomez, et al. Journal of Steroid Biochemistry and Molecular Biology 202 (2020) 105719

References

[1] E.M. Bloch, S. Shoham, A. Casadevall, B.S. Sachsai, B. Shaz, J.I. Winters, C. van Buskirk, B.J. Grossman, M. Joynner, J.P. Henderson, A. Pekosz, B. Lau, A. Wensloowski, L. Katz, H. Shan, P.G. Auwaerter, D. Thomas, D.J. Sullivan, N. Paneth, E. Gebrie, S. Spitalnik, E. Hod, L. Pollack, W.T. Nicholson, L. Pirofki, J.A. Bailey, A.A.R. Tobian, Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. (2020). https://doi.org/10.1172/JCI128745.

[2] J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, NEJMoa2007764 NEJMoa2007764. NEJMoa2007764.

[3] R. Bouillon, C. Marcocci, G. Carmeliet, D. Bille, J.H. White, B. Dawson-Hughes, P. Lips, C.F. Munoz, M. Lazaretti-Castro, A. Giustina, J. Bilezikian, Skeletal and extraskeletal actions of vitamin d: current evidence and outstanding questions, J.M. Quesada-Gomez, et al. Journal of Steroid Biochemistry and Molecular Biology 202 (2020) 105719

Endocr. Rev. 40 (2019) 1109–1151, https://doi.org/10.1210/er.2018-00126.

[4] P.-J. Martens, C. Gysenmans, A. Verstuyf, C. Mathieu, Vitamin d’s effect on immune function, Nutrients. 12 (2020) 1248, https://doi.org/10.3390/nu12051248.

[5] D.D. Bille, S. Patzek, Y. Wang, Physiologic and pathophysiologic roles of extra renal CVPRP: a case report and review, Bone Rep. 8 (2018) 255–267, https://doi.org/10.1016/j.bonr.2018.02.004.

[6] A.R. Martinez, D.A. Jolliffe, R.L. Hooper, L. Greenberg, J.F. Aloia, P. Bergman, G. Dubnov-Raz, S. Espinostro, D. Gammans, A.A. Ginde, E.C. Goodall, C.C. Grant, C.J. Griffiths, W. Janssens, L. Kjeldsen, S. Manaseki-Holland, D. Maugier, D.R. Murdoch, R. Neale, J.S. Simpson, I. Stelmach, G.T. Kumar, M. Urashima, C.A. Camargo, Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data, BMJ 356 (2017), https://doi.org/10.1136/bmj.h6828.

[7] S. Handsdottir, M.M. Monick, S.L. Hinde, N. Lovan, D.C. Look, G.W. Hunninghake, Respiratory epithelial cells convert inactive vitamin d to its active form: potential effects on host defense, J. Immunol. 181 (2008) 7090–7099, https://doi.org/10.4049/jimmunol.181.10.7090.

[8] Z. Xu, L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, S. Liu, P. Zhao, H. Liu, Z. Yu, C. Bai, T. Gao, J. Song, P. Xia, J. Dong, J. Zhao, F.S. Wang, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Resp. Med. 8 (2020) 420–422, https://doi.org/10.1016/s2213-2600(20)30096-x.

[9] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xie, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497–506, https://doi.org/10.1016/s0140-6736(20)30185-5.

[10] N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Y. Qiu, J. Wang, Y. Liu, Y. Wei, J. Tian, Y. Bai, X. Zhang, S. Wang, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet 395 (2020) 507–513, https://doi.org/10.1016/s0140-6736(20)30117-1.

[11] G. Bellani, J.G. Laffey, T. Tham, E. Fan, L. Brochard, A. Esteban, L.Gattinoni, F.M. Flabbi, A. Van Aarlen, M.F. Menendez, B.T. Thompson, H. Wrigge, A.S. Slutsky, A. Pesenti, Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries, JAMA J. Med. Assoc. Sci. (2015) 316 (2015) 788–800, https://doi.org/10.1001/jama.2015.6283.

[12] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xie, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497–506, https://doi.org/10.1016/s0140-6736(20)30185-5.

[13] N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhao, X. Ma, D. Wang, W. Wu, G. Wu, G.F. Gao, W. Tan, A novel coronavirus from patients in China with pneumonia in 2019, N. Engl. J. Med. 382 (2020) 727–733, https://doi.org/10.1056/NEJMoa2001017.

[14] E. Fan, D. Brodie, A.S. Slutsky, Acute respiratory distress syndrome, JAMA 319 (2018) 698, https://doi.org/10.1001/jama.2018.21957.

[15] T.J. Standiford, P.A. Ward, Therapeutic targeting of acute lung injury and acute respiratory distress syndrome, Transl. Res. 167 (2016) 183–191, https://doi.org/10.1016/j.trsl.2015.04.015.

[16] I. Channappanavar, S. Pawlinski, Pathogenic human coronavirus infections: causes (small) lecture fees from Abiogen, Procter and Gamble, Fresenius, FAES farma and CERES.

Acknowledgements

This work was supported by grants COVID-011-2020 “Programa de Investigación clínica en COVID-19 de Andalucía”. Consejería de Salud y Familia. Fundación Progreso y Salud y Fundación para la Investigación Biomédica de Córdoba (FIBICO). Andalucía. Spain.
M. Ohswa, T. Koyama, K. Yamamoto, S. Hiroswa, S. Kamei, R. Kamiyama, 1α,25-Dihydroxyvitamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocyctic cells, counteracting the effects of tumor necrosis factor and oxidized LDL, Circulation 102 (2000) 2867–2872, https://doi.org/10.1161/01.CIR.102.23.2867.

K.I. Aihara, H. Azuma, M. Akaike, Y. Ibeda, M. Yamashita, T. Sudo, H. Hayashi, Y. Yamada, F. Endoh, M. Fujimura, T. Yoshida, H. Yamaguchi, S. Hashizume, M. Kato, K. Yoshimura, Y. Yamamoto, S. Kato, T. Matsumoto, Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice, J. Biol. Chem. 279 (2004) 35798–35802, https://doi.org/10.1074/jbc.M404655200.

J.M. Martinez-Moreno, C. Herencia, A.M. De Oca, J.R. Nuñez-Castañeda, M.E. Rodríguez-Ortiz, J.M. Díaz-Tocados, E. Peralba-Santaella, A. Camargo, A. Canalejo, M. Rodríguez, F. Velasco-Gimena, Y. Almaden, Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells, FASEB J. 30 (2016) 1367–1376, https://doi.org/10.1096/fj.15-272872.

W.X. Wu, D.R. He, Low vitamin D levels are associated with the development of deep venous thromboembolic events in patients with ischemic stroke, Clin. Appl. Thromb. Hemost. 24 (2018) 69S–75S, https://doi.org/10.1177/1076029618786574.

O. Topaloglu, M.S. Arslan, M. Karakose, B. Ucan, Z. Ginis, E. Cakir, E.T. Akaymak, M. Sahin, M. Ozbek, E. Cakal, T. Delibasi, Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency?, Clin. Appl. Thromb. Hemost. 21 (2015) 428–433, https://doi.org/10.1177/1076029613509477.

M.F. Holick, Medical progress: vitamin d deficiency, N. Engl. J. Med. 357 (2007) 266–281, https://doi.org/10.1056/NEJMra070553.

J.D. Skyler, C.A. Camargo, D. Wanstier, C.M.M. Lawes, L. Too, K.T. Khaw, R. Scragg, Effect of monthly, high-dose, long-term vitamin D on lung function: a randomized controlled trial, Nutrients 9 (2017), https://doi.org/10.3390/n9121153.

R.C. Dancer, D. Parekh, S. Lax, V. Souza, S. Cheng, C.R. Bassford, D. Park, D.G. Bartis, R. Mahida, A.M. Turner, E. Sapey, W. Wei, B. Naidu, P.M. Stewart, W.D. Fraser, K.B. Christopher, M.S. Cooper, F. Gao, D.M. Sansom, A.R. Martineau, G.D. Perkins, D.R. Thickett, Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS), Thorax 70 (2015) 617–624, https://doi.org/10.1136/thoraxjnl-2014-206648.

J.M. Quesada-Gomez, R. Bouillon, Is calcifediol better than cholecalciferol for vitamin D supplementation? Osteoporos. Int. 29 (2018) 1697–1711, https://doi.org/10.1007/s00198-018-4520-y.

J.G. Green, N. Ohmagari, D. Shin, G. Diaz, A. Asperge, A. Castagna, T. Feldt, G. Green, M.I. Green, F.X. Lescure, E. Nicastri, R. Oda, K. Yo, E. Quirós-Roldán, A. Studemeister, J. Redinski, S. Ahmed, J. Bernet, D. Chelliah, D. Chen, S. Chihara, S.H. Cohen, J. Cunningham, A. D’Arminio Monforte, S. Imai, H. Kato, G. Lapadula, E. L’Her, T. Moreno, M. Majumder, M. Massari, M. Mora-Billo, Y. Mutsh, D. Nguyen, E. Verweij, A. Zoufaly, A.O. Ojinsa, A. DeZure, V. Zhao, L. Zhong, A. Chokkalingam, E. Elboudwarej, L. Telap, L. TIMBS, I. Henne, S. Sellers, H. Caio, S.K. Tan, L. Winterbourne, P. Desai, R. Mera, A. Gaggero, R.P. Myers, D.M. Brainard, R. Childs, T. Flanigan, Compassionate use of remdesivir for patients with severe Covid-19, N. Engl. J. Med. (2020), https://doi.org/10.1056/nejmoa2007016.